Edatrexate

Edatrexate

SCHEMBL4676

CCC(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHFR P00374 13/20 1.00
FOLR1 P15328 2/20 0.82
SLC19A1 P41440 2/20 0.82
SLC46A1 Q96NT5 2/20 0.82
KDM4E B2RXH2 1/20 0.70
TLR4 O00206 1/20 0.70
MEN1 O00255 1/20 0.70
ALDH1A1 P00352 1/20 0.70
LMNA P02545 1/20 0.70
TP53 P04637 1/20 0.70
TYMS P04818 1/20 0.70
GLA P06280 1/20 0.70
POLB P06746 1/20 0.70
HMGB1 P09429 1/20 0.70
MAPT P10636 1/20 0.70
FOLR2 P14207 1/20 0.70
HPGD P15428 1/20 0.70
ALOX15 P16050 1/20 0.70
ALOX12 P18054 1/20 0.70
GART P22102 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Edatrexate SCHEMBL20769788 1.00 DHFR (1.00) DHFRFOLR1SLC19A1SLC46A1KDM4E
Edatrexate SCHEMBL29352085 1.00 DHFR (1.00) DHFRFOLR1SLC19A1SLC46A1KDM4E
Edatrexate SCHEMBL1650127 1.00 DHFR (1.00) DHFRFOLR1SLC19A1SLC46A1KDM4E
Pralatrexate SCHEMBL21633 0.90 DHFR (1.00) DHFRFOLR1SLC19A1SLC46A1KDM4E
Pralatrexate SCHEMBL29904921 0.90 DHFR (1.00) DHFRFOLR1SLC19A1SLC46A1KDM4E
Pralatrexate SCHEMBL29904925 0.90 DHFR (1.00) DHFRFOLR1SLC19A1SLC46A1KDM4E
Pralatrexate SCHEMBL15075302 0.90 DHFR (1.00) DHFRFOLR1SLC19A1SLC46A1KDM4E
Pralatrexate SCHEMBL1889869 0.90 DHFR (1.00) DHFRFOLR1SLC19A1SLC46A1KDM4E
Pralatrexate SCHEMBL2336143 0.90 DHFR (1.00) DHFRFOLR1SLC19A1SLC46A1KDM4E
Pralatrexate SCHEMBL29355142 0.90 DHFR (1.00) DHFRFOLR1SLC19A1SLC46A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 32395 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4748859-A2 CHEMICALLY AND PHOTOCHEMICALLY INITIATED CELL MEMBRANE BLEBBING TO INDUCE CELL VESICLE PRODUCTION, MODIFICATIONS THEREOF, AND USES THEREOF The Regents of the University of California (US) 2026-05-27 EP claimed
US-20260137678-A1 METHODS FOR TREATING OR PREVENTING NEUROENDOCRINE TUMOR FORMATION USING XPO1 INHIBITORS MEMORIAL SLOAN-KETTERING CANCER CENTER (US) 2026-05-21 US claimed
EP-4743490-A1 HUMANIZED ANTI-CD7 ANTIBODY Christian-Albrechts-Universität zu Kiel (DE) 2026-05-20 EP claimed
WO-2026099502-A1 NOVEL DRUG CONJUGATES FOR TESTING CELLULAR DRUG UPTAKE Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) 2026-05-15 WO claimed
US-20260130855-A1 GAMMA POLYGLUTAMATED ANTIFOLATES AND USES THEREOF L E A F HOLDINGS GROUP LLC (US) 2026-05-14 US claimed
US-20260116861-A1 ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) 2026-04-30 US claimed
US-20260115305-A1 LINKERS, CONJUGATES AND APPLICATIONS THEREOF GENEQUANTUM HEALTHCARE SUZHOU CO LTD (CN) 2026-04-30 US claimed
EP-4729063-A2 TREATMENT OF CANCER USING COENZYME Q10 COMBINATION THERAPIES BPGbio, Inc. (US) 2026-04-22 EP claimed
US-20260077056-A1 LINKER-PAYLOAD COMPOUND, CONJUGATES AND APPLICATIONS THEREOF GENEQUANTUM HEALTHCARE SUZHOU CO LTD (CN) 2026-03-19 US claimed
EP-4698185-A1 METHODS AND SYSTEMS FOR IMPROVING ANTI-CANCER THERAPIES Osasuna Therapeutics SA (CH) 2026-02-25 EP claimed
EP-0912535-A1 CONJUGATES OF CIS-DOCOSAHEXAENOIC ACID AND PACLITAXEL Neuromedica, Inc. (US) 1999-05-06 EP claimed
WO-1999001118-A2 ANTIOXIDANT ENHANCEMENT OF THERAPY FOR HYPERPROLIFERATIVE CONDITIONS ATHEROGENICS, INC. (US) 1999-01-14 WO claimed
EP-0877615-A1 COMBINATION THERAPY METHOD FOR TREATING CANCER USING EDATREXATE AND A TAXANE DERIVATIVE, E.G. PACLITAXEL Sloan-Kettering Institute For Cancer Research (US) 1998-11-18 EP claimed
WO-1998037898-A1 SYNERGISTICALLY ACTING ANTI-FUNGAL AGENTS THAT ARE INHIBITORS OF FOLATE METABOLISM, ESPECIALLY METHOTREXATE AND SULFAMETHOXAZOLE BARCLAY BARRY J (CA) 1998-09-03 WO claimed
WO-1997044336-A9 CONJUGATES OF CIS-DOCOSAHEXAENOIC ACID AND PACLITAXEL 1998-04-16 WO claimed
WO-1997048391-A2 METHODS AND COMPOSITIONS COMPRISING R-IBUPROFEN ADVANCED RESEARCH AND TECHNOLOGY INSTITUTE (US) 1997-12-24 WO claimed
WO-1997044336-A1 CONJUGATES OF CIS-DOCOSAHEXAENOIC ACID AND PACLITAXEL NEUROMEDICA, INC. (US) 1997-11-27 WO claimed
WO-1997044026-A1 COMPOSITIONS COMPRISING CONJUGATES OF CIS-DOCOSAHEXAENOIC ACID AND TAXOTERE NEUROMEDICA, INC. (US) 1997-11-27 WO claimed
WO-1997027858-A1 COMBINATION THERAPY METHOD FOR TREATING CANCER USING EDATREXATE AND A TAXANE DERIVATIVE, E.G. PACLITAXEL SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) 1997-08-07 WO claimed
WO-1993013102-A1 DEAZAAMINOPTERINS SOUTHERN RESEARCH INSTITUTE (US) 1993-07-08 WO claimed